Lavoltidine
 | |
| Systematic (IUPAC) name | |
|---|---|
|
[1-methyl-5-[3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino]-1,2,4-triazol-3-yl]methanol | |
| Clinical data | |
| Legal status |
|
| Routes of administration | Oral |
| Identifiers | |
| CAS Number | 76956-02-0 |
| ATC code | None |
| PubChem | CID 55473 |
| ChemSpider | 50093 |
| UNII | X16K5179V5 |
| Chemical data | |
| Formula | C19H29N5O2 |
| Molar mass | 359.47 g/mol |
| |
Lavoltidine (INN,[1] USAN, BAN; previously known as loxtidine, code name AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline)[2] as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.[3][4]
See also
- H2 receptor antagonist
- Sufotidine (analogous sequence in which sulfone replaces the hydroxyl group)
References
- ↑ "WHO Drug Information. Vol 4, No. 3, 1990. International Nonproprietary Names for Pharmaceutical Substances. Recommended International Nonproprietary Names (Rec. INN): List 30" (PDF). World Health Organization. p. 7. Retrieved 12 January 2016.
- ↑ "Drug Profile: Lavoltidine". AdisInsight. Springer International Publishing AG. Retrieved 12 January 2016.
- ↑ Washington, Neena (1991). Antacids and anti-reflux agents. Boca Raton: CRC Press. ISBN 0-8493-5444-7.
- ↑ Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8.
| ||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Thursday, January 14, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.